Drug Discovery

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neurology

Study opens up new therapeutic pathways in Alzheimer’s disease 

A research team from VIB-KU Leuven and the UK Dementia Research Institute has discovered how neurons die in Alzheimer’s disease, opening new pathways for potential future treatments.  A new research paper published in Science illustrates how neurons initiate a programmed form of cell death, known… Read More

#News

Human cell
#Appointment #Biotech #Drug discovery #Single-cell analysis

Cytomos appoints new director to assist commercialisation strategy  

Biotech company Cytomos has appointed a new Non-Executive Director in a bid to help accelerate plans to brings its cell analysis technology to market.   Dr Sharon Brownlow has joined as Non-Executive Director and will play a key role in helping Cytomos bring its Dielectric Spectroscopy (CDS)… Read More

#News

Scotland flag
#Advanced Therapies #CGT Catapult #Drug development #Scotland

UK network launches to boost advanced therapies in the north  

A new cooperative network designed to foster collaboration and boost the sharing of knowledge and expertise for the UK’s advanced therapies sector has been launched.  The ‘Scottish Advanced Therapy Medicinal Products (ATMP) and Vaccines Network’ specifically targets researchers in the north of the UK… Read More

#News

Next generation sequencing
#Drug discovery #In Focus Report #NGS

DDW In Focus eReport: The impact of NGS on drug discovery

Created by DDW and sponsored by Tecan, ‘The Rise of NGS and its impact on drug discovery’ is a free In Focus report available here.  Download this In Focus eReport to learn more about the landscape of next generation sequencing (NGS) and how it is impacting drug discovery and… Read More

#News

Bottles of pills
#Cancer research #Drug development #Drug discovery #Oncology #Screening

Identify metabolic target pathways in cancer drug discovery

The regulation of cellular bioenergetics is recognised as a key driver of cancer cell proliferation. Identifying key pathways that modulate bioenergetic metabolism is a promising strategy for developing novel therapeutics for cancer treatment. Discover more in this new App Note from Agilent entitled ‘Rapid Bioenergetic Functional Screening of Anticancer Drug… Read More

#News

#Artificial intelligence (AI) #Benchling #Drug discovery #Lab automation #Proscia #Webinar

The benefits and innovations in AI and lab automation

Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More

#News

#Cancer research #Drug development #Drug discovery #Oncology #Screening

Learn about the rapid bioenergetic functional screening of anticancer drug candidates

The regulation of cellular bioenergetics is recognised as a key driver of cancer cell proliferation. Identifying key pathways that modulate bioenergetic metabolism is a promising strategy for developing novel therapeutics for cancer treatment. In this App Note you will learn: How the Agilent Seahorse XF Real Time ATP rate assay… Read More

#Resources

#AI #Drug discovery #Generative AI #Machine learning #Webinar

Generative AI webinar: Turning drug discovery into a technological pursuit

This webinar supported by Thermo Fisher Scientific and presented by Generate:Biomedicines will be free to attend on 12 October 9am EDT / 2pm BST / 3pm CEST. The webinar, hosted by DDW, will feature the expertise of Adam Root, Vice President, Protein Sciences at Generate:Biomedicines who will discuss how an… Read More

#News

#App note #Assays #Drug development #Drug discovery #Kinetics #Sartorius

Download now: Optimise kinetic assays to avoid avidity effects

‘Optimising kinetic assays to avoid avidity effects’ – a new free resource – is now available from Sartorius and DDW. What you will learn: Researchers from ChromoTek discuss the differences between affinity and avidity as measured on the Octet BLI platform Measuring affinity in avidity driven assay orientations Why assay… Read More

#News

#AI / data analytics / healthtech / informatics #Biotechnology #Drug development #Drug discovery #Technology

This week in drug discovery (11-15 September)  

News round-up for 11-15 September by DDW Digital Content Editor Diana Spencer. Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development. Read More

#News

Job hire
#Appointment #Drug development #Europe

Norgine appoints new COO to drive European position  

Specialist pharmaceutical company Norgine has appointed Saulo Martiniano as its new Chief Operating Officer (COO).  Martiniano previously worked at L’Oréal and was responsible for leading Global Manufacturing Excellence across 38 plants that included more than 10,000 employees.  Martiniano will now be based in the UK and… Read More

#News

#Assays #Drug development #Drug discovery #Kinetics

Optimising kinetic assays to avoid avidity effects

What you will learn: Researchers from ChromoTek discuss the differences between affinity and avidity as measured on the Octet® BLI platform Measuring affinity in avidity driven assay orientations Why assay orientation, valency, ligand surface density and non-specific binding matter Recognise and resolve issues arising from interactions that contain a bivalent… Read More

#Resources

microRNA
#App note #Drug development #Drug discovery #mRNA #Purification technology #Screening

App Note: Achieve mRNA binding with DBC values over 6mg/mL

A new Application Note is now available to download from Sartorius BIA Separations. In this App Note, multi-parallel screening of binding conditions on CIM Oligo dT 96-well plates was performed to optimise the dynamic binding capacity (DBC) in the shortest time possible. What you will learn: How to effectively use Monolithic 96-well plates… Read More

#News

#Drug development #Drug discovery #mRNA #Purification technology #Screening

Discover how to achieve mRNA binding on Oligo dT with DBC values over 6mg/mL

In this Application Note, multi-parallel screening of binding conditions on CIM® Oligo dT 96-well plates was performed to optimise the dynamic binding capacity (DBC) in the shortest time possible. What you will learn: How to effectively use Monolithic 96-well plates when developing methods. They are unique on the market in combining the… Read More

#Resources

Cancer cells
#Bispecific therapeutics #Cancer research #Collaboration #Drug development #Immatics #Moderna #mRNA

Multi-platform collab to develop innovative oncology therapeutics 

Moderna and Immatics have announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high, unmet medical need.   This broad multi-platform collaboration will leverage the scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s… Read More

#Cancer Research #News

Cancer cells
#biological engineering #Bolt Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Immunology

New podcast: In conversation with Shelley Ackerman, Bolt Biotherapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Shelley… Read More

#News